Genmab — September 2020
-
Det bliver interessant at se hvad der sker med kursen når USA åbner.
-
Det lyder overvejende sandsynligt
Du er lidt af en spåmand 
-
Det virker som om nogle i markedet mener Genmab skal bære hele byrden af JNJs betaling til HALO. Men når jeg læser følgende sætning,så vil jeg mene det er max. en 1/5-del af HALO betalingen som Genmab skal bære: Janssen has started reducing its royalty payments to Genmab by what it claims to be Genmab’s share of Janssen’s royalty payments to Halozyme for the second quarter of 2020.
-
Da Genmab får max 20% i royalties, så kan Genmabs andel af skaden vel ikke overstige en 1/5-del?
-
Det var også dette regnestykke jeg havde i hovedet i morges da jeg skrev at det worst case kun kunne dreje sig om en mindre del af royaltyen Genmab eventuelt skal betale.
-
Ja, hvis ikke Hexa-cd38 kan tager over inden...
-
Konkurrence fra andre medicinalfirmaer vil vel være grund nok til at de vil drive HexaCD38 frem?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind